{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:31:53Z","timestamp":1793413913972,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s43441-026-01017-8","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:31:58Z","timestamp":1784313118000},"page":"1795-1804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Serious Breach Cases Reported in the EU Clinical Trials Information System: Quantitative and Qualitative Assessment"],"prefix":"10.1007","volume":"60","author":[{"given":"Ewelina","family":"Wodnicka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Swieczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"1017_CR1","unstructured":"European Parliament and Council of the European Union. Regulation (EU) No 536\/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001\/20\/EC. Off J Eur Union. 2014;L158:1\u201376. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-regulation."},{"key":"1017_CR2","unstructured":"European Medicines Agency. Mandatory use of CTIS from 31 January 2023 for all new clinical trial applications. 2026. https:\/\/www.ema.europa.eu\/en\/news\/mandatory-use-ctis-31-january-2023-all-new-clinical-trial-applications. Accessed 27 April 2026."},{"key":"1017_CR3","unstructured":"European Medicines Agency. Clinical trials\u2019 transition to new EU system: one year left. 2026. https:\/\/www.ema.europa.eu\/en\/news\/clinical-trials-transition-new-eu-system-one-year-left. Accessed 27 April 2026."},{"key":"1017_CR4","unstructured":"European Medicines Agency. Clinical trials information system (CTIS) for sponsors [Internet]. Amsterdam: European Medicines Agency; 2026. Available from: https:\/\/euclinicaltrials.eu\/ctis-for-sponsors\/?lang=en."},{"key":"1017_CR5","unstructured":"European Medicines Agency, Heads of Medicines Agencies. Guideline for the notification of serious breaches of Regulation (EU) No 536\/2014 or the clinical trial protocol. London: European Medicines Agency; 2023. EMA\/698382\/2021."},{"issue":"4","key":"1017_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s43441-021-00269-w","volume":"55","author":"L Galuchie","year":"2021","unstructured":"Galuchie L, Stewart C, Meloni F. Protocol deviations: a holistic approach from defining to reporting. Ther Innov Regul Sci. 2021;55(4):733\u201342.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"1017_CR7","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s43441-022-00401-4","volume":"56","author":"K Getz","year":"2022","unstructured":"Getz K, Smith Z, Jain A, Krauss R. Benchmarking protocol deviations and their variation by major disease categories. Ther Innov Regul Sci. 2022;56(4):632\u20136.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"1017_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cpt.2386","volume":"112","author":"NA Khin","year":"2022","unstructured":"Khin NA, Grandinetti C, Dixey H, et al. Tackling challenging data integrity topics in 2020: update on good clinical practice perspectives from the US FDA and MHRA UK. Clin Pharmacol Ther. 2022;112(1):31\u201343.","journal-title":"Clin Pharmacol Ther"},{"key":"1017_CR9","unstructured":"Avoca Group. 6 questions answered about serious breach reporting [Internet]. Fort Washington (PA): Avoca Group; 2026. Available from: https:\/\/theavocagroup.com\/6-questions-answered-about-serious-breach-reporting."},{"key":"1017_CR10","first-page":"118","volume":"2","author":"M Malinowska-W\u00f3jcicka","year":"2023","unstructured":"Malinowska-W\u00f3jcicka M. Access to clinical trial dossiers and documents submitted for the marketing authorisation of a medicinal product under the provisions on access to public information. Int Law Q. 2023;2:118\u201340.","journal-title":"Int Law Q"},{"key":"1017_CR11","unstructured":"Ustawa z dnia 9 marca 2023 r. o badaniach klinicznych produkt\u00f3w leczniczych stosowanych u ludzi. Dz U. 2023 poz. 605."},{"key":"1017_CR12","unstructured":"Accelerating Clinical Trials in the EU (ACT EU). Report to monitor the European clinical trials environment (January\u2013March 2025) [Internet]. Amsterdam: European Medicines Agency; 2025. Available from: https:\/\/accelerating-clinical-trials.europa.eu\/document\/download\/a9886721-f614-4c17-a3dc-53137a63d7bc_en?filename=ACT%20EU%20KPI%20Report%20Jan-Mar%202025.pdf."},{"key":"1017_CR13","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline: Guideline for good clinical practice E6(R3). Final version. 2025."},{"key":"1017_CR14","unstructured":"European Medicines Agency. Reflection paper on risk based quality management in clinical trials. London: European Medicines Agency; 2013. EMA\/269011\/2013."},{"issue":"6","key":"1017_CR15","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1177\/2168479014530119","volume":"48","author":"M Mehra","year":"2014","unstructured":"Mehra M, Kurpanek K, Petrizzo M, Brenner S, McCracken Y, Katz T, et al. The life cycle and management of protocol deviations. Ther Innov Regul Sci. 2014;48(6):762\u201377. https:\/\/doi.org\/10.1177\/2168479014530119.","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"1017_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/2229-3485.184817","volume":"7","author":"RB Ghooi","year":"2016","unstructured":"Ghooi RB, Bhosale N, Wadhwani R, Divate P, Divate U. Assessment and classification of protocol deviations. Perspect Clin Res. 2016;7(3):132\u20136. https:\/\/doi.org\/10.4103\/2229-3485.184817.","journal-title":"Perspect Clin Res"},{"key":"1017_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-214","volume":"12","author":"EA Sweetman","year":"2011","unstructured":"Sweetman EA, Doig GS. Failure to report protocol violations in clinical trials: a threat to internal validity? Trials. 2011;12:214. https:\/\/doi.org\/10.1186\/1745-6215-12-214.","journal-title":"Trials"},{"issue":"5","key":"1017_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/qshc.2008.028605","volume":"19","author":"JM Taekman","year":"2010","unstructured":"Taekman JM, Stafford-Smith M, Velazquez EJ, Wright MC, Phillips-Bute BG, Pfeffer MA, et al. Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve. Qual Saf Health Care. 2010;19(5):405\u201310. https:\/\/doi.org\/10.1136\/qshc.2008.028605.","journal-title":"Qual Saf Health Care"},{"issue":"4","key":"1017_CR19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s43441-023-00506-4","volume":"57","author":"O Akpoviroro","year":"2023","unstructured":"Akpoviroro O, Castagne-Charlotin M, Joyce NP, Malikova MA. Assessment of the relationship between protocol adherence, study complexity and personnel in surgical clinical trials. Ther Innov Regul Sci. 2023;57(4):619\u201328. https:\/\/doi.org\/10.1007\/s43441-023-00506-4.","journal-title":"Ther Innov Regul Sci"},{"issue":"5","key":"1017_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s43441-025-00828-5","volume":"59","author":"F Ibelli","year":"2025","unstructured":"Ibelli F, Bozzo R, Pezzi J, Moledous I, Ojanguren G, Iannantuono R. Incidence and characterization of important protocol deviations in clinical trials in Argentina. Ther Innov Regul Sci. 2025;59(5):1171\u20138. https:\/\/doi.org\/10.1007\/s43441-025-00828-5.","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"1017_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/17407745241232430","volume":"21","author":"MJ Gooden","year":"2024","unstructured":"Gooden MJ, Norato G, Landry K, Martin SB, Nath A, Reoma L. Rethinking the clinical research protocol: lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance. Clin Trials. 2024;21(4):491\u20139. https:\/\/doi.org\/10.1177\/17407745241232430.","journal-title":"Clin Trials"},{"issue":"3","key":"1017_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/17407745241304059","volume":"22","author":"M Fronc","year":"2025","unstructured":"Fronc M, Jakubczyk M, Love SB, Talbot S, Rolfe T. Central statistical monitoring in clinical trial management: a scoping review. Clin Trials. 2025;22(3):342\u201351. https:\/\/doi.org\/10.1177\/17407745241304059.","journal-title":"Clin Trials"},{"issue":"3","key":"1017_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s43441-024-00613-w","volume":"58","author":"S de Viron","year":"2024","unstructured":"de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does central statistical monitoring improve data quality? An analysis of 1,111 sites in 159 clinical trials. Ther Innov Regul Sci. 2024;58(3):483\u201394. https:\/\/doi.org\/10.1007\/s43441-024-00613-w.","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"1017_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s43441-022-00496-9","volume":"57","author":"A Adams","year":"2021","unstructured":"Adams A, Adelfio A, Barnes B, Berlien R, Branco D, Coogan A, et al. Risk-based monitoring in clinical trials: 2021 update. Ther Innov Regul Sci. 2021;57(3):529\u201337. https:\/\/doi.org\/10.1007\/s43441-022-00496-9.","journal-title":"Ther Innov Regul Sci"},{"key":"1017_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s43441-024-00719-1","volume":"59","author":"N Stansbury","year":"2025","unstructured":"Stansbury N, Branco D, McDavid C, Stewart J, Surdam K, Olson N, et al. Risk-based quality management: a case for centralized monitoring. Ther Innov Regul Sci. 2025;59:199\u2013210. https:\/\/doi.org\/10.1007\/s43441-024-00719-1.","journal-title":"Ther Innov Regul Sci"},{"key":"1017_CR26","unstructured":"European Medicines Agency. Revised CTIS transparency rules. Amsterdam: European Medicines Agency; 2023. EMA\/263067\/2023."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01017-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:02:37Z","timestamp":1793412157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01017-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01017-8","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}